NCT07895160Recruiting
Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
OCEAN: Organ Culture for Endocrine Resistant Next Line - Treatment Selection Based on Fresh Tumor Samples in Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy. A biopsy sample from each participant will be tested using an ex vivo organ culture (EVOC) platform, which preserves the tumor tissue and allows researchers to assess its response to different anticancer treatments. The results will be used to help select the participant's next systemic treatment. The main objective is to evaluate the proportion of patients whose cancer responds to treatment selected using this approach. The study will also assess how long the cancer remains controlled, overall survival, and the relationship between laboratory test results and clinical outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 14 Jun 2024
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07895160
What you commit to
- Study type: Interventional
- Planned participants: 39
- From 14 Jun 2024 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chemotherapy within 3 weeks before biopsy or aspiration.
- Any severe concurrent disease that, in the investigator's judgment, makes the patient unsuitable for study participation.
- Treatment with another investigational drug within 14 days before study entry.
Other illness
- Positive test for acquired immunodeficiency syndrome (AIDS).
- Positive hepatitis B or hepatitis C testing indicating acute or chronic infection.
Other
- Pregnancy or breastfeeding.
- Inability to exercise judgment.
Who the study is looking for
- Patients progressing on endocrine therapy, with or without biological therapy, who are candidates for their first non-endocrine-based line of treatment.
- Patients expected to receive treatment for metastatic breast cancer within the coming weeks.
- Age 18 years or older.
- Life expectancy of at least 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tel-Aviv Sourasky Medical Center Coordinator of this site? Confirm its status | Tel Aviv | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.